Dissecting complex traits: Recent advances in hypertension genomics

Genome Medicine

Volumn 1, Issue 4, 2009, Pages

  O'Shaughnessy, Kevin M ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; ATENOLOL; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DEBRISOQUINE; METOPROLOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; PROTEIN SERINE THREONINE KINASE; SODIUM CHLORIDE COTRANSPORTER;

DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; GENE CLUSTER; GENE FREQUENCY; GENE LOCUS; GENOME ANALYSIS; GENOMICS; GORDONIA AMARAE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

EID: 77953425627     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm43     Document Type: Review

References (41)

1. Swales JD: Platt Versus Pickering: an Episode in Recent Medical History. Cambridge: Keynes Press; 1985.
2. Reich DE, Lander ES: On the allelic spectrum of human disease. Trends Genet 2001, 17:502-510.
3. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U, Danesh J: Association of apolipoprotein e genotypes with lipid levels and coronary risk. JAMA 2007, 298:1300-1311.
4. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
5. Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, Hinokio Y, Lindner TH, Mashima H, Schwarz PEH, del Bosque-Plata L, Horikawa Y, Oda Y, Yoshiuchi I, Colilla S, Polonsky KS, Wei S, Concannon P, Iwasaki N, Schulze J, Baier LJ, Bogardus C, Groop L, Boerwinkle E, Hanis CL, Bell GI: Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000, 26:163-175.
6. Caulfield M, Munroe P, Pembroke J, Samani N, Dominiczak A, Brown M, Benjamin N, Webster J, Ratcliffe P, O'Shea S, Papp J, Taylor E, Dobson R, Knight J, Newhouse S, Hooper J, Lee W, Brain N, Clayton D, Lathrop GM, Farrall M, Connell J: Genome-wide mapping of human loci for essential hypertension. Lancet 2003, 361:2118-2123.
7. The International HapMap Project [http://www.hapmap.org].
8. Salanti G, Sanderson S, Higgins JP: Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 2005, 7:1 3-20.
9. Levy D, Larson M, Benjamin E, Newton-Cheh C, Wang T, Hwang SJ, Vasan R, Mitchell G: Framingham Heart Study 100K Project: genome-wide associations for blood pressure and arterial stiffness. BMC Med Genet 2007, 8:S3.
10. The Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
11. Kahle KT, Ring AM, Lifton RP: Molecular physiology of the WNK kinases. Annu Rev Physiol 2008, 70:329-355.
12. Newhouse SJ, Wallace C, Dobson R, Mein C, Pembroke J, Farrall M, Clayton D, Brown M, Samani N, Dominiczak A, Connell JM, Webster J, Lathrop GM, Caulfield M, Munroe PB: Haplotypes of the WNK1 gene associate with blood pressure variation in a severely hypertensive population from the British Genetics of Hypertension study. Hum Mol Genet 2005, 14:1805-1814.
13. Tobin MD, Raleigh SM, Newhouse S, Braund P, Bodycote C, Ogleby J, Cross D, Gracey J, Hayes S, Smith T, Ridge C, Caulfield M, Sheehan NA, Munroe PB, Burton PR, Samani NJ: Association of WNK1 gene polymorphisms and haplotypes with ambulatory blood pressure in the general population. Circulation 2005, 112:3423-3429.
14. Scuteri A, Sanna S, Chen WM, Uda M, Albai G, Strait J, Najjar S, Nagaraja R, Orru M, Usala G, Dei M, Lai S, Maschio A, Busonero F, Mulas A, Ehret GB, Fink AA, Weder AB, Cooper RS, Galan P, Chakravarti A, Schlessinger D, Cao A, Lakatta E, Abecasis GR: Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet 2007, 3:e115.
15. Loos RJF, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, Inouye M, Freathy RM, Attwood AP, Beckmann JS, Berndt SI, Bergmann S, Bennett AJ, Bingham SA, Bochud M, Brown M, Cauchi S, Connell JM, Cooper C, Smith GD, Day I, Dina C, De S, Dermitzakis ET, Doney ASF, Elliott KS, Elliott P, Evans DM, Sadaf Farooqi I, Froguel P, et al.: Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008, 40:768-775.
16. Ehret GB, Morrison AC, O'Connor AA, Grove ML, Baird L, Schwander K, Weder A, Cooper RS, Rao DC, Hunt SC, Boerwinkle E, Chakravarti A: Replication of the Wellcome Trust genome-wide association study of essential hypertension: the Family Blood Pressure Program. Eur J Hum Genet 2008, 16:1507-1511.
17. Org E, Eyheramendy S, Juhanson P, Gieger C, Lichtner P, Klopp N, Veldre G, Doring A, Viigimaa M, Sober S, Tomberg K, Eckstein G, KORA, Kelgo P, Rebane T, Shaw-Hawkins S, Howard P, Onipinla A, Dobson RJ, Newhouse SJ, Brown M, Dominiczak A, Connell J, Samani N, Farrall M, BRIGHT, Caulfield MJ, Munroe PB, Illig T, Wichmann HE, et al.: Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Hum Mol Genet 2009, [Epub ahead of print].
18. Wang Y, O'Connell JR, McArdle PF, Wade JB, Dorff SE, Shah SJ, Shi X, Pan L, Rampersaud E, Shen H, Kim JD, Subramanya AR, Steinle NI, Parsa A, Ober CC, Welling PA, Chakravarti A, Weder AB, Cooper RS, Mitchell BD, Shuldiner AR, Chang YP: From the cover: wholegenome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci USA 2009, 106:226-231.
19. Richardson C, Rafiqi FH, Karlsson HKR, Moleleki N, Vandewalle A, Campbell DG, Morrice NA, Alessi DR: Activation of the thiazidesensitive Na+-Cl-- cotransporter by the WNK-regulated kinases SPAK and OSR1. J Cell Sci 2008, 121:675-684.
20. Christopher Newton-Cheh, Toby Johnson, Vesela Gateva, Martin D Tobin, Murielle Bochud, Lachlan Coin, Samer S Najjar, Jing Hua Zhao, Simon C Heath, Susana Eyheramendy, Konstantinos Papadakis: Eight blood pressure loci identified by genome-wide association study of 34,433 people of European ancestry. Nat Genet 2009, in press.
21. Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JI, Uitterlinden AG, Harris TB, Witteman JCM, Boerwinkle E, on behalf of the CHARGE Consortium: Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet 2009, 2:73-80.
22. Lifton RL: Genetic dissection of human blood pressure variation: common pathways from rare phenotypes. Harvey Lect 2004, 100:71-101.
23. Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, Newton-Cheh C, State M, Levy D, Lifton RP: Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008, 40:592-599.
24. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O, Wang TJ: Association of common variants in NPPA and NPPB with circulatingnatriuretic peptides and blood pressure. Nat Genet 2009, 41:348-353.
25. Torkamani A, Topol EJ, Schork NJ: Pathway analysis of seven common diseases assessed by genome-wide association. Genomics 2008, 92:265-272.
26. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992, 51:197-205.
27. Filigheddu F, Argiolas G, Bulla E, Troffa C, Bulla P, Fadda S, Zaninello R, Degortes S, Frau F, Pitzoi S, Glorioso N: Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians. Pharmacogenomics 2008, 9:1419-1427.
28. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ: Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995, 13:1602-1609.
29. Sandilands A, O'Shaughnessy KM: The functional significance of genetic variation within the beta1-adrenoceptor. Br J Clin Pharmacol 2005, 60:235-243.
30. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF: ?1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003, 74:44-52.
31. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, Zhou HH: Gly389Arg polymorphism of ?1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003, 74:372-379.
32. O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ: The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci 2000, 99:233-238.
33. Beitelshees AL, Zineh I, Yarandi HN, Pauly DF, Johnson JA: Influence of phenotype and pharmacokinetics on ?-blocker drug target pharmacogenetics. Pharmacogenomics J 2006, 6:174-178.
34. The PharmacoGenomics Knowledge Base [http://www.pharmgkb.org/index.jsp].
35. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-DeHoff RM, Gums J, Curry RW, Gong Y, Beitelshees AL, Schwartz G, Turner ST: Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 2009, 157:442-449.
36. Pacanowski MA, Gong Y, Cooper-DeHoff RM, Schork NJ, Shriver MD, Langaee TY, Pepine CJ, Johnson JA: ?-Adrenergic receptor gene polymorphisms and ?-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008, 84:715-721.
37. The Anglo-Scandiniavian Cardiac Outcome Trial [http://www.ascotstudy.org/home.htm].
38. Lesko LJ, Salerno RA, Spear BB, Anderson DC, Anderson T, Brazell C, Collins J, Dorner A, Essayan D, Gomez-Mancilla B, Hackett J, Huang SM, Ide S, Killinger J, Leighton J, Mansfield E, Meyer R, Ryan SG, Schmith V, Shaw P, Sistare F, Watson M, Worobec A: Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J Clin Pharmacol 2003, 43:342-358.
39. The SEARCH Collaborative Group: SLCO1B1 Variants and statininduced myopathy - a genomewide study. N Engl J Med 2008, 359:789-799.
40. Bijl MJ, Visser LE, van Schaik RHN, Kors JA, Witteman JCM, Hofman A, Vulto AG, van Gelder T, Stricker BHC: Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in ?-blocker users. Clin Pharmacol Ther 2008, 85:45-50.
41. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom SM: British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004, 328:634-640.